Ovarian CancerNCT06617585
The Role of CircDENND4C in Epithelial Ovarian Cancer
An observational study of Ovarian Cancer, run by Assiut University.
Trial summary
circular RNAs (circRNAs), a newly discovered type of endogenous noncoding RNAs [8], are involved in the regulation of various biological functions. They act by sponging off certain microRNAs (miRNAs) and play a role in the pathogenesis of many diseases, including cancers [9-11]. Read more about this study
- Who is it for?
- Ages 18 to 75 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Ovarian Cancer
- How many people
- 30 participants
- Where
- No sites listed yet
- Study dates
- 1 Dec 2024to 1 Oct 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Study population: apparently healthy group and group of known diagnosed as ovary cancer in assiut uni hospital
Who may be able to join
- patients at South Egypt Cancer institute and Recently diagnosed ovarian cancer patients 2. Patients not went to surgery.
Who cannot join
- . Patients receive any anti-cancer therapy. 2. Patients diagnosed with other concomitante cancer or chronic disease
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
circular RNAs (circRNAs), a newly discovered type of endogenous noncoding RNAs [8], are involved in the regulation of various biological functions. They act by sponging off certain microRNAs (miRNAs) and play a role in the pathogenesis of many diseases, including cancers [9-11]. In addition, circRNAs are not com- monly degraded by RNA enzymes present in body flu- ids [8], and most of them possess expression specificity at the tissue, cell, and developmental stage level [12,13]. Thus, they can be ideal clinica
Read the detailed description
epithelial OC (EOC), the most common form of OC, accounts for 90% of all OC cases [2]. EOC has the highest mortality among all gynecologic tumors and poses a serious threat to women's life [3].herefore, early clinical diagnosis is crucial. Commonly used laboratory indicators for OC diagnosis
- Conditions
- Ovarian Cancer
- Medical subject headings
- Ovarian Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
role of circDENND4c in the diagnosis of ovarian cancer
by quality real time PCR we use the circDENND4c as a tumour marker for ovarian cancer
Measured: baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Sep 2024
- Study start1 Dec 2024 (estimated)
- Primary completion2 Feb 2028 (estimated)
- Study completion1 Oct 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ovarian CancerStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Marwa Mamdouh Mohamed Abdellah, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06617585
- Sponsor's protocol ID
- CircDENND4C in ovarian cancer
- Status last verified
- Sep 2024
- First submitted
- 27 Nov 2023
- Last updated
- 27 Sep 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Sep 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Role of CircDENND4C in Epithelial Ovarian Cancer
- ClinicalTrials.gov ID
- NCT06617585
- Acronym / sponsor ID
- CircDENND4C in ovarian cancer
- Conditions
- Ovarian Cancer
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 Dec 2024 (estimated)
- Primary completion
- 2 Feb 2028 (estimated)
- Study completion
- 1 Oct 2028 (estimated)
- First posted
- 27 Sep 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
circular RNAs (circRNAs), a newly discovered type of endogenous noncoding RNAs [8], are involved in the regulation of various biological functions. They act by sponging off certain microRNAs (miRNAs) and play a role in the pathogenesis of many diseases, including cancers [9-11]. In addition, circRNAs are not com- monly degraded by RNA enzymes present in body flu- ids [8], and most of them possess expression specificity at the tissue, cell, and developmental stage level [12,13]. Thus, they can be ideal clinica
Detailed description
epithelial OC (EOC), the most common form of OC, accounts for 90% of all OC cases [2]. EOC has the highest mortality among all gynecologic tumors and poses a serious threat to women's life [3].herefore, early clinical diagnosis is crucial. Commonly used laboratory indicators for OC diagnosis
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 to 75 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- apparently healthy group and group of known diagnosed as ovary cancer in assiut uni hospital
Key inclusion criteria (1 listed)
- patients at South Egypt Cancer institute and Recently diagnosed ovarian cancer patients 2. Patients not went to surgery.
Key exclusion criteria (1 listed)
- . Patients receive any anti-cancer therapy. 2. Patients diagnosed with other concomitante cancer or chronic disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
role of circDENND4c in the diagnosis of ovarian cancer
Time frame: baseline
by quality real time PCR we use the circDENND4c as a tumour marker for ovarian cancer
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Sep 2024.
- Individual participant dataSharing planned: No
Related trials for Ovarian Cancer
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Recruiting
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Ovarian Carcinoma
RecruitingPhase 2
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Ovarian Cancer, Fallopian Tube Cancer
Active, not recruitingPhase 1/2
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
Colorectal Neoplasms, Breast Neoplasms
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Ovarian Cancer, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 27 Sep 2024. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Marwa MamDouh Mohamed (20+1153538300, marwaamamdouh26@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
role of circDENND4c in the diagnosis of ovarian cancer (time frame: baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Sep 2024.